Pharmaceutical Preparations · DE · CIK 1953926
Develops and commercializes immunology-based therapies for autoimmune diseases, focusing on obexelimab
Comparable business profile · signals at a glance
In the 90 days to Mar 31, 2026: 3 insiders bought $6.3M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 31, 2026 | Lu HongboDirector | Buy | 75,000 | $20.00 | $1.5M |
| Mar 31, 2026 | Moulder Leon O JrChief Executive Officer | Buy | 34,000 | $19.31 | $657K |
| Mar 30, 2026 | Moulder Leon O JrChief Executive Officer | Buy | 20,000 | $18.23 | $365K |
| Feb 13, 2026 | Allen Patricia LDirector | Buy | 4,160 | $26.36 | $110K |
| Feb 12, 2026 | Allen Patricia LDirector | Buy | 5,700 | $24.34 | $139K |
| Feb 12, 2026 | Allen Patricia LDirector | Buy | 5,000 | $26.50 | $133K |
| Feb 12, 2026 | Allen Patricia LDirector | Buy | 5,000 | $23.77 | $119K |
| Feb 11, 2026 | Lu HongboDirector | Buy | 25,985 | $22.50 | $585K |
| Feb 2, 2026 | Moulder Leon O JrChief Executive Officer | Buy | 57,000 | $17.96 | $1.0M |
| Jan 9, 2026 | Moulder Leon O JrChief Executive Officer | Buy | 20,000 | $16.55 | $331K |
| Jan 8, 2026 | Moulder Leon O JrChief Executive Officer | Buy | 30,000 | $16.30 | $489K |
| Jan 7, 2026 | Moulder Leon O JrChief Executive Officer | Buy | 50,000 | $16.38 | $819K |
| Oct 9, 2025 | Enright Patrick GDirector | Buy | 105,265 | $19.00 | $2.0M |
| Oct 9, 2025 | Sr One Capital Management, LlcTenPercentOwner | Buy | 63,158 | $19.00 | $1.2M |
| Oct 9, 2025 | Nunn Jason RaleighDirector | Buy | 63,158 | $19.00 | $1.2M |
| Oct 9, 2025 | Sr One Capital Management, LlcTenPercentOwner | Buy | 63,157 | $19.00 | $1.2M |
| Oct 9, 2025 | Enright Patrick GDirector | Buy | 11,990 | $20.85 | $250K |
| Oct 7, 2025 | Harwin Peter EvanDirector | Buy | 316,219 | $19.00 | $6.0M |
| Oct 7, 2025 | Lu HongboDirector | Buy | 263,160 | $19.00 | $5.0M |
| Oct 7, 2025 | Moulder Leon O JrSee Remarks | Buy | 36,928 | $20.85 | $770K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.